Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis

Reuters

07-18

<a href="https://laohu8.com/S/VTRS">Viatris Inc.</a> Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis

Viatris Inc., a global healthcare company, has announced the results of several key clinical trials. The company reported positive top-line results from its Phase 3 LYNX-2 trial of MR-142, aimed at keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Additionally, Viatris shared positive outcomes from its second pivotal Phase 3 VEGA-3 trial of MR-141, focused on treating presbyopia. However, the Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. Viatris is currently evaluating the next steps for the MR-139 Phase 3 program, which may include revising the planned additional study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE32851) on July 18, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2552464452"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552464452\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2552464452?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-18 18:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552464452","market":"fut","top_or_hot":-1,"title":"Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VTRS\">Viatris Inc.</a> Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viatris Inc., a global healthcare company, has announced the results of several key clinical trials. The company reported positive top-line results from its Phase 3 LYNX-2 trial of MR-142, aimed at keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Additionally, Viatris shared positive outcomes from its second pivotal Phase 3 VEGA-3 trial of MR-141, focused on treating presbyopia. However, the Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. Viatris is currently evaluating the next steps for the MR-139 Phase 3 program, which may include revising the planned additional study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE32851) on July 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-18 18:59</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VTRS\">Viatris Inc.</a> Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viatris Inc., a global healthcare company, has announced the results of several key clinical trials. The company reported positive top-line results from its Phase 3 LYNX-2 trial of MR-142, aimed at keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Additionally, Viatris shared positive outcomes from its second pivotal Phase 3 VEGA-3 trial of MR-141, focused on treating presbyopia. However, the Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. Viatris is currently evaluating the next steps for the MR-139 Phase 3 program, which may include revising the planned additional study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE32851) on July 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL1XjCnT:1","article_id":"2552464452","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552464452","pubTimestamp":1752836361,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis. Viatris Inc., a global healthcare company, has announced the results of several key clinical trials. The company reported positive top-line results from its Phase 3 LYNX-2 trial of MR-142, aimed at keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Additionally, Viatris shared positive outcomes from its second pivotal Phase 3 VEGA-3 trial of MR-141, focused on treating presbyopia. However, the Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. Viatris is currently evaluating the next steps for the MR-139 Phase 3 program, which may include revising the planned additional study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide acc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4588":"碎股","VTRS":"Viatris Inc.","BK4007":"制药","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4583":"猴痘概念"},"translate_title":"Viatris Inc.宣布MR-142和MR-141 3期试验的积极结果，并提供MR-139睑缘炎研究的最新情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":0.9},"content_text":"Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis\n    \n\n        Viatris Inc., a global healthcare company, has announced the results of several key clinical trials. The company reported positive top-line results from its Phase 3 LYNX-2 trial of MR-142, aimed at keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Additionally, Viatris shared positive outcomes from its second pivotal Phase 3 VEGA-3 trial of MR-141, focused on treating presbyopia. However, the Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. Viatris is currently evaluating the next steps for the MR-139 Phase 3 program, which may include revising the planned additional study.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE32851) on July 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}